GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MagForce AG (OTCPK:MGFRF) » Definitions » Debt-to-EBITDA

MagForce AG (MagForce AG) Debt-to-EBITDA : -3.47 (As of Dec. 2021)


View and export this data going back to 2013. Start your Free Trial

What is MagForce AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MagForce AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.00 Mil. MagForce AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $28.97 Mil. MagForce AG's annualized EBITDA for the quarter that ended in Dec. 2021 was $-8.35 Mil. MagForce AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -3.47.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MagForce AG's Debt-to-EBITDA or its related term are showing as below:

MGFRF's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.24
* Ranked among companies with meaningful Debt-to-EBITDA only.

MagForce AG Debt-to-EBITDA Historical Data

The historical data trend for MagForce AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MagForce AG Debt-to-EBITDA Chart

MagForce AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 2.34 -2.60 1.24 -3.69

MagForce AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.02 -3.34 0.52 -4.08 -3.47

Competitive Comparison of MagForce AG's Debt-to-EBITDA

For the Medical Devices subindustry, MagForce AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MagForce AG's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MagForce AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MagForce AG's Debt-to-EBITDA falls into.



MagForce AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MagForce AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 28.973) / -7.856
=-3.69

MagForce AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 28.973) / -8.346
=-3.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2021) EBITDA data.


MagForce AG  (OTCPK:MGFRF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


MagForce AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MagForce AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MagForce AG (MagForce AG) Business Description

Traded in Other Exchanges
N/A
Address
Max-Planck-Stresse 3, Berlin, DEU, 12489
MagForce AG is a medical engineering company. The company operates in the area of nanotechnology-based cancer treatment. Its medical devices include NanoTherm therapy used for local treatment of solid tumors, NanoTherm a liquid that reacts to the presence of a magnetic field, NanoPlan uses the bioheat transfer equation, and NanoActivator used for tumors in all areas of the body.

MagForce AG (MagForce AG) Headlines